Just an FYI....Fine’s post had little false information. The one item that I could see as false is the FDA’s requirement for a company to have good financials for BLA submission. Obviously a company needs money to submit the BLA but I highly doubt the FDA cares about a biotechs financials when considering drug approval.

Her tone could be labeled as bashing and maybe her attempt to link information, but I don’t see why we couldn’t respond with legit facts.

The BOD member who left is a BOD member for various companies. He assists smaller companies, makes money, gets stock and moves on. No different for his time at CYDY. Linking his departure to RP’s removal has no basis.